key: cord-0871797-3i5nh7oa
authors: Vlachogianni, Glykeria; Hassapopoulou-Matamis, Helen; Politis, Constantina; Fylaki, Eirini; Mentis, Andreas
title: A case of COVID-19 Convalescent Plasma Donation in Greece: directed donation for compassionate use in the donor's critically ill father
date: 2020-09-25
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2020.09.001
sha: efd9da91ab01f732139a1d78390215eed8432d8d
doc_id: 871797
cord_uid: 3i5nh7oa

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

To the Editor

In line with the position paper of the WHO Blood Regulators Network published in 2017, the use of convalescent plasma has been considered as a therapeutic option in the COVID-19 pandemic [1] [2] [3] [4] . It was reported to be beneficial to severely affected patients in some early observational studies and preliminary uncontrolled case series [5] [6] [7] . However, it was not always possible to determine whether the observed improvement could have been related to therapies other than the COVID-19 convalescent plasma (CCP). All published reports before the present one refer to donations of CCP from unrelated donors, whereas we present a case of directed CCP use in a critically ill patient with COVID-19.

The patient, a 66-year-old man with fever, was initially prescribed clarithromycin, and subsequently admitted to hospital because of radiographic evidence of bilateral pulmonary infiltrates. As a result of clinical deterioration and confirmation by molecular testing of the presence of SARS-CoV-2 genetic material, he was transferred on the 8 th day from onset of the disease to a reference Intensive Care Unit. He was intubated and treated with hydroxychloroquine, lopinavir/ritonavir and a combination of moxifloxacin, meropenem, and linezolid; later with colimycin, linezolid and ceftazidime-avibactam and finally with colimycin plus tigecyclin and anidulafungin, when colonization with multi-resistant bacteria and fungi was revealed. By the 17 th day from onset he was severely ill, haemodynamically unstable, with compromised renal and hepatic function, needing high doses of inotropic agents and continuous intravenous corticosteroid infusion, in serious respiratory distress despite high ventilator settings.

During the pandemic, the Greek Ministry of Health broadcast local and international information daily, including therapeutic modalities worldwide. Although at that time, no official clinical trial had been announced in Greece and no CCP units had been collected, the use of CCP was beginning to emerge and, hearing this, the patient's adult son (himself a confirmed COVID-19 patient, with mild disease symptoms and same symptom onset time as his father) investigated the possibility of offering plasma as a therapeutic last resort, by contacting the Coordinating Centre for Haemovigilance and Surveillance of Transfusion (SKAEM) of the Hellenic National Public Health Organization (NPHO). He was instructed to wait until at least 28 days from the onset or 14 days from the end of symptoms and to be retested before donating (two consecutive negative molecular tests for the virus before donation or at least one negative test on the donation day are required). The clinicians explained that this delay could compromise the outcome, and that the use of CCP might be of little or no benefit to a patient with such bad prognostic indices 8 .

The patient's son's persistence and pleading led to scheduling the directed plasma donation. It was clear that the inevitably delayed administration of his plasma to the patient could offset the possible beneficial effect, but at least it was not expected to harm him. The candidate donor and the recipient were blood group compatible. The donor had no prior history of blood transfusion, therefore anti-HLA and anti-HPA antibodies would be absent.

Since he was a first-time donor, it was decided to proceed with the donation of one whole blood unit, not plasmapheresis. All required donor selection and blood screening criteria were in accordance with the relevant Greek legislation for blood donors. Molecular testing of a nasopharyngial sample taken on the donation day (31 st day from disease onset) was negative. Detection of neutralizing antibodies in the donor's serum was not performed, since it is not mandatory in the EU programme of COVID-19 CCP collection and transfusion 9 . However, specific anti-SARS-CoV-2 IgG and IgA antibodies in the donor's serum were detected and measured using a commercial kit. The plasma was separated and kept frozen until administered to the patient on the 33 rd day from onset, after all necessary procedures had been completed (proxy signed consent forms, approval from the Institutional Ethical and Scientific Committee). No adverse reactions associated with the 200 ml plasma infusion (performed slowly over 4 hours) were observed. The condition of the patient remained critical and he expired from cardiopulmonary arrest in the context of septic shock, on the 37 th day after onset of the disease.

As far as we Know, this was the first CCP administration in Greece (on April 20, 2020). Among the general issues arising from this case, we wish to draw attention to the problems related to the lack of CCP stock, leading to the failure of crucial timely CCP administration and to the specific safety measures required when one has to rely on family members.

GV, and EF were responsible for the integrity and accuracy of clinical data of the patient and researched data for the article. CP coordinated the study, was responsible for recruiting the CCP donor, counseling the clinical team, researched data for the article and provided critical revision of the manuscript. CP and HHM were responsible for clinical data of the CCP donor, the conceptual framing and drafting the manuscript. AM was responsible for the serologic investigation and offered critical advice

The Authors declare no conflict of interests.

WHO Blood Regulators Network, Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus

Use of convalescent plasma therapy in SARS patients in

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

China puts 245 COVID-19 patients on convalescent plasma therapy. News release. Xinhua

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Effectiveness of CCP therapy in severe COVID-19 patients

Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three Month Experience

An EU programme of COVID-19 CCP collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored use. Version 1